Chi Advisors LLC Cullinan Oncology, Inc. Transaction History

Chi Advisors LLC

$203 Million
Q3 2023

A detailed history of Chi Advisors LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Chi Advisors LLC holds 3,414,189 shares of CGEM stock, worth $29.2 Million. This represents 15.23% of its overall portfolio holdings.

Number of Shares

3,414,189

Previous 3,414,189 -0.0%

Holding current value

$29.2 Million

Previous $36.7 Million 15.89%

% of portfolio

15.23%

Previous 13.81%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$8.8 - $13.4 $569,615 - $867,368	64,729 Added 1.93%	3,414,189 $36.7 Million
Q1 2023 May 11, 2023	BUY	$10.2 - $11.91 $325,543 - $380,119	31,916 Added 0.96%	3,349,460 $34.3 Million
Q4 2022 Feb 13, 2023	BUY	$9.72 - $13.62 $722,769 - $1.01 Million	74,359 Added 2.29%	3,317,544 $35 Million
Q3 2022 Nov 09, 2022	BUY	$11.82 - $15.42 $2.31 Million - $3.02 Million	195,576 Added 6.42%	3,243,185 $41.6 Million
Q2 2022 Aug 12, 2022	BUY	$7.31 - $13.55 $2.15 Million - $3.99 Million	294,562 Added 10.7%	3,047,609 $39.1 Million

Q1 2022 May 16, 2022	BUY	$10.47 - $16.75 $2.89 Million - $4.63 Million	276,327 Added 11.16%	2,753,047 $28.8 Million
Q4 2021 Feb 11, 2022	BUY	$15.36 - $25.0 $3.56 Million - $5.8 Million	231,879 Added 10.33%	2,476,720 $38.2 Million
Q3 2021 Nov 15, 2021	BUY	$22.56 - $29.68 $45,120 - $59,360	2,000 Added 0.09%	2,244,841 $50.7 Million
Q2 2021 Aug 11, 2021	BUY	$24.96 - $41.25 $1.01 Million - $1.67 Million	40,434 Added 1.84%	2,242,841 $57.8 Million
Q1 2021 May 14, 2021	BUY	$28.0 - $53.42 $61.7 Million - $118 Million	2,202,407 New	2,202,407 $91.8 Million

Others Institutions Holding CGEM

# of Institutions

149

Shares Held

65.1M

Call Options Held

10.7K

Put Options Held

14.4K

View Full List

About Cullinan Oncology, Inc.

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $390M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

More about CGEM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Chi Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chi Advisors LLC with notifications on news.

Account